Oculis Stock Shock: Eye-Drop Trial Miss Sends Shares Sliding
Oculis shares fell 23.4% to $22.70 after two Phase 3 trials of its OCS-01 eye drops in diabetic macular edema failed to meet their main vision goal. The company said it will not seek U.S. approval for OCS-01 in this indication. After-hours trading saw shares drop further to $18.35. Trading volume reached 2.76 million, well above average.